References: |
Product Reference:
?Effects of xanthine derivatives on lipolysis and on adenosine 3',5'- monophosphate phosphodiesterase activity: J.A. Beavo, et al.; Mol. Pharmacol. 6, 597 (1970)
?Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine: P. Janik, et al.; Cancer Res. 40, 1950 (1980)
?A role for soluble cAMP phosphodiesterases in differentiation of 3T3-L1adipocytes: M.L. Elks & V.C. Manganiello; J. Cell Physiol. 124, 191 (1985)
?Adenosine receptors: development of selective agonists and antagonists: J.W. Daly, et al.; Prog. Clin. Biol. Res. 230, 41 (1987)
?Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors: J.A. Beavo & D.H. Reifsnyder; TIPS 11, 150 (1990)
?Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity: C. Tomes, et al.; Cell Signal. 5, 615 (1993)
?IBMX induces calcium release from intracellular stores in rat sensory neurones: Y. Usachev & A. Verkhratsky; Cell Calcium 17, 197 (1995)
?Inhibition of recombinant human cardiac L-type Ca2+ channel alpha1C subunits by 3-isobutyl-1-methylxanthine: I.M. Fearon, et al.; Eur. J. Pharmacol. 342, 353 (1998)
?Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas: T.C. Chen, et al.; Lab. Invest. 78, 165 (1998)
?The phosphodiesterase inhibitor IBMX suppresses TNF-alpha expression in human adipocyte precursor cells: a possible explanation for its adipogenic effect: F. Hube, et al.; Horm. Metab. Res. 31, 359 (1999)
?Cyclic nucleotide phosphodiesterases: D.M. Essayan; J. Allergy Clin. Immunol. 108, 671 (2001)
?Leukotrienes: underappreciated mediators of innate immune responses: M. Peters-Golden, et al.; J. Immunol. 174, 589 (2005)
? |